Effect of Propofol and Sevoflurane Anesthesia on HSP70 Expression in Tumor Cells

NCT ID: NCT06626711

Last Updated: 2025-05-04

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-10
• Study Completion Date: 2025-12-30

Brief Summary

The goal of this clinical trial is to learn if sevoflurane-based inhalational anesthesia (s-IA) and propofol-based total intravenous anesthesia (p-TVA) have different effects on HSP70 expression in different types of tumour cells. The main questions it aims to answer are:

• if p-TVA/s-IA increase or suppress HSP70 expression in tumor cells in comparison with a pre-anesthesia level;
• does this change in HSP70 expression cause any difference in vital characteristics of tumor cells, such as proliferation, apoptosis, colony formation and migration.

Researchers will compare p-TVA with s-IA by ability of these types of anesthesia to change the HSP70 expression level and modulate HSP70-mediated effects in tumor cells.

Participants will:

• be randomly allocated to p-TVA or s-IA groups;
• donate 12 ml of blood before anesthesia induction and 12 ml after 2 hours of anesthesia.

The blood serum will be used to prepare cell medium. After exposure to this medium, cells from different tumor types will be investigated using cytological and molecular biological methods.

Detailed Description

This study will be conducted in adult cancer patients who undergo planned radical or palliative tumor resection and signed informed consent. Patients with diabetes mellitus, HIV, hepatitis B and C, as well as patients who undergo emergency surgery will not be included to the study. Patients will be randomly allocated to propofol-based TVA (p-TVA) and sevoflurane-based IA (s-IA) groups. After the collection of blood before the anesthesia induction and in 2 hours of anesthesia, probes will be centrifuged to prepare serum. Cell medium will contain 50% of blood serum. Different tumor cell lines (human lung adenocarcinoma A549, large cell lung carcinoma NCI-H460, human colorectal adenocarcinoma DLD1) will be exposed to the cell medium for 4 hours what corresponds to an approximate duration of anesthesia for oncology surgery. HSP70 expression level will be determined using SDS-PAGE (polyacrilamide gel electrophoresis) and Western-blot analysis (intracellular HSP70 content), ELISA of cell medium (extracellular HSP70 expression) and confocal microscopy.

The A549 cell line with stable knockdown of HSP70 developed by shRNA will be used to distinguish HSP70-based effects of cell medium from p-TVA and s-IA groups on vital characteristics of tumor cells, including proliferation (MTT assay), apoptosis (LDH cytotoxicity assay), colony formation and migration (the Wound healing assay).

Researchers will compare HSP70 expression levels and vital characteristics of tumor cells exposed to patient serum before and after each type of anesthesia, as well as p-TVA group with s-IA group.

Conditions

Anesthesia; Cancer Recurrence; Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Propofol-based total venous anesthesia group

These patients will receive total venous anethesia where propofol is used as a hypnotic drug.

Group Type: EXPERIMENTAL

Propofol

Intervention Type: DRUG

Propofol as a part of total venous anesthesia

Sevoflurane-based inhalational anesthesia group

These patients will receive inhalational anethesia where sevoflurane is used as a hypnotic drug.

Group Type: EXPERIMENTAL

Sevoflurane

Intervention Type: DRUG

Sevoflurane as a part of intravenous anesthesia

Interventions

Propofol

Propofol as a part of total venous anesthesia

Intervention Type: DRUG

Sevoflurane

Sevoflurane as a part of intravenous anesthesia

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosed malignant neoplasm
• Planned surgery for radical or palliative tumor resection
• Age over 18 years
• Signed informed consent

Exclusion Criteria

• Diabetes mellitus type 2
• HIV, hepatitis B or C
• Emergency surgery
• Known or suspected allergy to studied drugs
• Other conditions when one of the types of anesthesia is more preferable (hemodynamic disorders, bronchial asthma etc)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institute of Cytology of the Russian Academy of Sciences

UNKNOWN

Sponsor Role: collaborator

The Russian Science Foundation

UNKNOWN

Sponsor Role: collaborator

Saint Petersburg State University, Russia

OTHER

Sponsor Role: lead

Responsible Party

Efremov Sergey

Deputy director for science, Saint-Petersburg state university hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Saint Petersburg State University Hospital

Saint Petersburg, , Russia

Countries

Russia

Other Identifiers

23-25-00078

Identifier Type: -

Identifier Source: org_study_id